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StrokeCytochrome c (Cytc) and cytochrome c oxidase (COX) catalyze the terminal reaction of the mitochondrial
electron transport chain (ETC), the reduction of oxygen to water. This irreversible step is highly regulated, as
indicated by the presence of tissue-speciﬁc and developmentally expressed isoforms, allosteric regulation,
and reversible phosphorylations, which are found in both Cytc and COX. The crucial role of the ETC in health
and disease is obvious since it, together with ATP synthase, provides the vast majority of cellular energy,
which drives all cellular processes. However, under conditions of stress, the ETC generates reactive oxygen
species (ROS), which cause cell damage and trigger death processes. We here discuss current knowledge of
the regulation of Cytc and COX with a focus on cell signaling pathways, including cAMP/protein kinase A and
tyrosine kinase signaling. Based on the crystal structures we highlight all identiﬁed phosphorylation sites on
Cytc and COX, and we present a new phosphorylation site, Ser126 on COX subunit II. We conclude with a
model that links cell signaling with the phosphorylation state of Cytc and COX. This in turn regulates their
enzymatic activities, themitochondrial membrane potential, and the production of ATP and ROS. Our model is
discussed through two distinct human pathologies, acute inﬂammation as seen in sepsis, where
phosphorylation leads to strong COX inhibition followed by energy depletion, and ischemia/reperfusion
injury, where hyperactive ETC complexes generate pathologically high mitochondrial membrane potentials,
leading to excessive ROS production. Although operating at opposite poles of the ETC activity spectrum, both
conditions can lead to cell death through energy deprivation or ROS-triggered apoptosis. This article is part of
a Special Issue entitled: “Respiratory Oxidases”.iratory Oxidases”.
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In multicellular organisms communication between cells and
within subcellular compartments is essential to coordinate diverse
cellular and overall organ functions. The communication system in
higher organisms utilizes a battery of mechanisms such as hormonal
regulation through the bloodstream, electrical conduction to transmit
signals in neurons, and small molecules or ions inside the cell such ascAMP and calcium. Cell signaling pathways streamline communica-
tion within and among cells. Central roles are played by receptors,
kinases, phosphatases, and scaffolding proteins that together generate
a speciﬁc signal that eventually leads to the chemical modiﬁcation, i.e.,
phosphorylation or dephosphorylation of downstream target pro-
teins. A key cellular unit, themitochondrial oxidative phosphorylation
(OxPhos) machinery, is currently being explored for evidence of
regulation by cell signaling pathways.
The primary role of OxPhos is the provision of energy, which drives
all cellular processes. An average human synthesizes 65 kg of ATP
from ADP and phosphate per day [1], highlighting the importance of
this process for organismal health. A secondary role is the participa-
tion of OxPhos in apoptosis, a concerted sequence of events including
changes in OxPhos activity, mitochondrial membrane potential
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release of cytochrome c, formation of the apoptosome, and execution
of apoptosis via caspase activation. Given the dual role of OxPhos in
cellular life and death decisions, tight regulation is warranted.
OxPhos generates more than 15 times the amount of ATP
compared to anaerobic glycolysis. OxPhos consists of the electron
transport chain (ETC) and ATP synthase. The ETC consists of NADH
dehydrogenase (complex I), succinate dehydrogenase (complex II),
the non-protein electron carrier ubiquinone, bc1-complex (complex
III), cytochrome c (Cytc), and cytochrome c oxidase (COX; complex
IV). Electrons enter the ETC primarily via complex I from NADH.
Complex II links OxPhos with the citric acid cycle and feeds electrons
derived from succinate directly into the ubiquinone/ubiquinol pool.
Except for complex II, which does not function as a proton pump, the
other ETC complexes pump protons from the matrix into the
intermembrane space, generating the mitochondrial membrane
potential (ΔΨm). ΔΨm is utilized by ATP synthase (complex V) to
synthesize ATP from ADP and phosphate, driven by the backﬂow of
protons from the mitochondrial intermembrane space to the matrix.
In contrast to many unicellular organisms including yeast, which can
grow and survive in the absence of oxygen, animals fully depend on
aerobic energy metabolism, with few exceptions restricted to parts of
the organism, such as the fetus during the ﬁrst half of pregnancy [2],
and cancer, where the exception is known as theWarburg effect [3,4].
2. Regulation of mitochondrial OxPhos
In the following sections we review the multifaceted regulation of
mitochondrial respiration through respiratory control, tissue-speciﬁc
isoforms, allosteric regulation, and post-translational modiﬁcations,
which will be the basis for the subsequent discussion of the role of
OxPhos in selected human diseases.
2.1. The traditional view of the regulation of mitochondrial OxPhos:
respiratory control
Depending on the activity of the cell, cellular energy demand
varies widely and energy production thus has to be adjusted
accordingly. The traditional principle by which OxPhos is controlled
is called respiratory control, ﬁrst described by Lardy and Wellman [5]
as stimulation of mitochondrial respiration by a phosphate acceptor
(e.g., ADP), and later extended by Chance and Williams [6] as an
inhibition of respiration during transition from state 3 (high rate) to
state 4 (low rate), when ADP is converted to ATP.
When cells utilize energy ATP is converted into ADP, which is
converted back into ATP by ATP synthase using the proton gradient.
This reduction in ΔΨm allows the proton pumps to resume electron
transfer and to pump protons across the inner membrane. When cells
are at rest and the vast majority of ADP has been converted into ATP,
ATP synthesis slows, and ΔΨm builds up, which inhibits the proton
pumps and thus mitochondrial respiration. When working with
isolated mitochondria two extreme states are often reported to
characterize mitochondrial function: state 3 respiration after the
addition of ADP and phosphate in the presence of complex I or II
substrates, which gives maximal respiration rates, and state 4, when
all ADP has been converted into ATP, which gives low respiration rates
(state 1 is baseline respiration of mitochondria in the absence of
substrates; state 2 is deﬁned as respiration after the addition of ETC
substrates such as succinate but in the absence of exogenous ADP).
Analysis of respiratory states of isolated mitochondria is useful to
determine the number of ATP molecules produced per oxygen
consumed, which is referred to as the P/O ratio; the ratio of state
3/state 4 respiration serves as a measure of mitochondrial “tightness”
or coupling and is referred to as the respiratory control ratio.
Respiratory control is the most basic level of regulation and is
deﬁned by substrate concentrations. For example, substrates forcomplexes I and II, and ADP and phosphate for ATP synthase, and the
reaction intermediates and products, such as ΔΨm generated by the
proton pumps and ATP generated by ATP synthase, all affect the
respiration rate. However, additional regulatory mechanisms exist, as
recently established for mammalian COX and Cytc, and these will be
discussed.
2.2. Tissue-speciﬁc isoforms of cytochrome c oxidase and cytochrome c
In contrast to OxPhos complexes I, II, III, and V, for which no tissue
speciﬁc isoforms have been reported, both Cytc and COX occur as
distinct tissue-speciﬁc isozymes in mammals. This suggests that the
terminal step of the ETC, i.e., the electron transfer from Cytc to O2 via
COX, has to be functionally adapted to tissue-speciﬁc energy needs.
2.2.1. Cytochrome c
Mammalian Cytc is a one-electron carrier that shuttles electrons
from bc1 complex to COX. It contains a covalently attached heme
group and 104 amino acids (Fig. 1, top left). Cytc is highly positively
charged with a pI of 9.6 and is located in the mitochondrial
intermembrane space, where it is associated with negatively charged
phospholipids of the inner membrane, in particular cardiolipin.
In rodents, Cytc occurs as a testes-speciﬁc isoform (Cytc-T), which
is expressed in the germinal epithelial cells [7], and a somatic isoform
(Cytc), which is expressed in all other tissues. In humans there is only
a single functional Cytc gene because the Cytc testis isoform gene was
lost during primate evolution. The former Cytc-T in humans is now a
non-transcribed pseudogene [8,9].
In mice the two Cytc isoforms share 86% sequence identity but
their enzymatic functions are clearly distinct as discussed elsewhere
[10]. For example, Cytc-T shows a threefold increased activity to
reduce hydrogen peroxide compared with the somatic isoform, but
also shows an approximately fourfold increased ability to induce
apoptosis [11]. The authors proposed that these functional changes
may prevent radical damage of sperm and at the same time serve as a
selective agent by initiating apoptosis in damaged sperm. In addition
to its role in respiration, as a ROS scavenger under healthy conditions,
and as an initiator of apoptosis, Cytc participates in several other
activities including Erv1-Mia40-coupled protein import, cardiolipin
oxidation during apoptosis, and p66shc-coupled ROS production
(reviewed in [10]), where it would be interesting to assess possible
differences between the Cytc isoform pair.
2.2.2. Cytochrome c oxidase
COX is the terminal enzyme of the ETC. It accepts electrons from
reduced Cytc and transfers them to molecular oxygen, which is
reduced to water. This reaction is coupled to the transfer of protons
from the matrix to the intermembrane space by COX. In addition to
these ‘pumped’ protons COX takes up ‘chemical’ protons, which are
needed when oxygen is reduced to water. Both pumped and chemical
protons contribute to ΔΨm. Cow heart COX has been crystallized as a
dimer [12]. Per monomer, mammalian COX is composed of two heme
and two copper redox centers located in catalytic subunits I and II.
COX contains 13 subunits, three of which are encoded by the
mitochondrial DNA and ten by nuclear DNA (Fig. 1).
For six of the smaller, nuclear-encoded subunits tissue-speciﬁc
isoforms have been identiﬁed. All isoforms are encoded by separate
genes and are not generated through differential splicing. Three liver-
and heart-type isoform pairs of subunits VIa, VIIa, and VIII exist, which
have long been known (reviewed in [13]). Liver-type COX is
expressed in most organs such as liver, brain, and kidney, whereas
the heart-type isozyme is expressed in heart and skeletal muscle.
Heart-type COX is expressed in tissues with a high aerobic capacity
and a large number of mitochondria, whereas other tissues including
the brain cannot afford such a high mitochondrial load due to their
specialized functions. Since these tissues still fully depend on aerobic
Fig. 1. Mapped phosphorylation sites on cytochrome c and cytochrome c oxidase. Crystal structure data of horse heart cytochrome c [119] and cow heart COX [12] were used and
processed with the program Swiss-PDBViewer 3.7. Identiﬁed phosphorylated amino acids inmammals are shown in sticks. See Table 1 for a detailed description of the sites including
phospho-epitopes and references. Note that Thr52 in rabbit corresponds to Ser52 in cow COX subunit IV.
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liver-type. In addition, we recently identiﬁed three more COX subunit
isoforms. These are a lung-speciﬁc isoform of COX subunit IV (COX4-
2), a testis-speciﬁc isoform of subunit VIb, and a third isoform of
subunit VIII [9,14,15].
Functional data including enzyme kinetics have so far been
reported only for the better-studied liver, heart, and lung isozymes
showing that enzymatic activity follows the order heart-type b liver-
type b lung-type [16,17]. The reason for lung COX being the highest
activity enzyme is not clear. It was proposed that the expression of
COX4-2 in lung, a highly oxygenated tissue, might drain electrons
from the ETC leaving fewer substrate electrons for the formation of
ROS [17,18].
2.3. Allosteric regulation of cytochrome c and cytochrome c oxidase
Another regulatory mechanism found in key metabolic enzymes is
allosteric regulation, which allows ﬁne-tuning of enzymatic activity
based on the concentrations of reaction substrates, intermediates, and
products. A common mechanism found in COX and Cytc is that theybind adenine nucleotides. At physiological concentrations, ATP binds
to Cytc, which changes the binding of Cytc to COX, leading to an
inhibition of the reaction between Cytc and COX, and the elimination
of the low Km phase of the otherwise biphasic kinetics with COX [19].
For COX, the largest nuclear-encoded subunit, subunit IV, has been
shown to bind ATP at the matrix side [20,21]. ATP binding leads to an
allosteric inhibition of enzyme activity at high intra-mitochondrial
ATP/ADP ratios, adjusting energy production to demand. It was then
proposed that COX subunit IV is a pivotal regulator for COX activity in
higher organisms in contrast to bacteria that lack this subunit [22,23].
COX subunit Va, which localizes to the matrix (Fig. 1), was shown
to bind the thyroid hormone T2. Upon binding, the allosteric ATP
inhibition is released, allowing a high turnover even at high ATP/ADP
ratios [24].
The muscle speciﬁc isoform of subunit VIa was suggested to
decrease the pumped proton-to-electron stoichiometry at high
ATP/ADP ratios, in contrast to the VIa liver-type-containing isozyme,
which pumps protons at a high ratio independently of the ATP/ADP
ratio [25]. However, liver-type COX shows a reduced proton/electron
stoichiometry after addition of palmitate [26].
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(NO), which competes with O2 for binding at the binuclear heme a3–
CuB reaction center [27]. Altered NO concentrations are found in a
variety of human diseases including amyotrophic lateral sclerosis,
cancer [28], arthritis [29], sepsis and septic shock [30], trauma [31],
neurodegenerative diseases [32], and obesity and diabetes [33].
Elevated levels of NO result in COX inhibition and overall reduced
ETC ﬂux, leading to decreased energy levels, which might at least in
part explain some aspects of NO-related pathologies.
2.4. Regulation of cytochrome c and cytochrome c oxidase by
phosphorylation
Research analyzing other compartments of the cell including the
plasma membrane, cytosol, and nucleus has long established the
central role of cell signaling in the regulation and functioning of the
living cell. However, mitochondria have only recently been recog-
nized as targets of cell signaling pathways, and are now rousing from a
century-long hibernation. Phosphorylation sites have been identiﬁed
in all OxPhos complexes, but the signaling pathways involved
including kinases and phosphatases remain unknown or uncertain
in most cases [34]. Phosphorylation of Cytc and COX has been most
intensively studied, both structurally and functionally, and those
phosphorylations will be discussed in detail, including a new
phosphorylation site in COX subunit II that we present here. In Cytc
and COX, 4 and 14 phosphorylation sites have been mapped,
respectively, mainly through mass spectrometry (MS) (Fig. 1 and
Table 1). MS methodology has become increasingly sensitive and can
be operated in a high throughput manner. More and more such data
sets are available now, including a study on human skeletal muscle
showing phosphorylation of Cytc Thr28 and Ser47 [35], and a study on
human HeLa cells that indicated phosphorylation of COX subunit IV-1
Ser67 and Ser136 COX subunit Va Thr35 and Thr38 [36] (see Fig. 1 and
Table 1). Such information is important but two points clearly need to
be addressed: 1) What are the functional consequences of individual
phosphorylations, and 2) How much of the protein is phosphorylated
at a given condition, i.e., what are the dynamics of these phosphor-
ylations. Below we summarize the known phosphorylations on Cytc
and COX and focus our discussion on phosphorylations and signaling
pathways that affect the function of Cytc and COX.Table 1
Identiﬁed phospho-epitopes in mammalian cytochrome c and cytochrome c oxidase1.
Enzyme Species & tissue Phosphorylated amino
acid2
Phospho-epitope3
Cytc
Cytc
Human skeletal muscle
Human skeletal muscle
Thr28
Ser47
EKGGKHKTGPNLHGL
TGQAPGYSYTAANKN
Cytc Cow liver Tyr48 GQAPGFSYTDANKKN
Cytc Cow heart Tyr97 EREDLIAYLKKATNE
COX
COX
Cow liver
Cow liver
Tyr304, SU I
Tyr304, SU I
MDVDTRAYFTSATMI
MDVDTRAYFTSATMI
COX
COX
COX
COX
COX
Rabbit heart
Cow heart
Cow liver
Cow heart
HeLa cells
Ser115 and Ser116, SU I
Ser126, SU II
Tyr11, SU IV-1
Ser34, SU IV-1
Ser67, SU IV-1
SLHLAGVSSILGAINF
DSYMIPTSELKPGEL
SVVKSEDYALPSYVD
VAHVKNLSASQKALK
YRIKFKESFAEMNRG
COX
COX
COX
COX
COX
Rabbit heart
HeLa cells
Cow heart
Cow heart
HeLa cells
Thr52, SU IV-1
Ser136, SU IV-1
Ser4, SU Va
Thr35, SU Va
Thr35 and Thr38, SU Va
KAPWGSLTRDEKVEL
NPIQGLASKWDYEKN
SHGSHETDEEF
ELRKGMNTLVGYDLV
LRKGINTLVTYDMVPE
COX Rabbit heart Ser40, SU Vb MLPPKAASGTKEDPN
COX Cow heart Thr11, SU VIa AKGDHGGTGARTWRF
1 Identiﬁed phosphorylation sites are presented in an ascending amino acid and subunit
2 Numbering according to mature peptide based on cow.
3 Sequence is based on the species where the phosphorylation site was identiﬁed.
4 Based on the Scansite Motif Scan web tool (http://scansite.mit.edu/motifscan_seq.phtm
5 High throughput mass spectrometry sequencing.2.4.1. Phosphorylation of cytochrome c
After Cytc had been studied formore than a century, we discovered
that it is the target of cell signaling pathways. We isolated Cytc from
cow heart tissue under conditions that preserve the physiological
phosphorylation state and found, by MS, that it was phosphorylated
on Tyr97 (Fig. 1) [37]. The phosphorylated form showed functional
differences, including a shift of the heme iron–methionine 80
absorption band from 695 to 687 nm. In addition, phosphorylated
Cytc showed enhanced sigmoidal kinetics and inhibition in the
reaction with COX by shifting the Km of COX for Cytc. Half maximal
turnover was observed at a Cytc substrate concentration of 5.5 μM
compared to 2.5 μM for unphosphorylated Cytc.
We later analyzed Cytc phosphorylation in cow liver tissue and, to
our surprise, found that it was phosphorylated on a different residue,
Tyr48 [38]. There were no spectral changes, and enzyme kinetics with
isolated COX was distinct compared to Tyr97-phosphorylated heart
Cytc. Tyr48-phosphorylated Cytc produced a hyperbolic response,
similar to unphosphorylated Cytc. At maximal turnover, COX activity
was more than 50% reduced with Tyr48-phosphorylated Cytc. The
ﬁnding of partial (but not full) respiratory inhibition with in vivo
Tyr97- and Tyr48-phosphorylated Cytc in heart and liver supports our
model that, under healthy conditions, ETC activity does not operate at
full capacity, undoubtedly to prevent ΔΨm hyperpolarization. This
prevents the production of signiﬁcant amounts of ROS, which are
generated at high ΔΨm levels, a concept we discuss in Section 3.
In a follow-up study we generated and puriﬁed phosphomimetic
Cytcby replacingCytcTyr48withGlu,whichmimics thenegative charge
of the phosphate group. Similar effects compared to in vivo Tyr48-
phosphorylated Cytc were observed in the reaction with COX, suggest-
ing that it is a good model for phosphorylated Cytc. Tyr48Glu Cytc
showed reduced binding afﬁnity to cardiolipin, a mitochondria-speciﬁc
lipidwithwhich it is normally associated. Strikingly, the ability of Cytc to
trigger down-streamcaspase activationwas completely abolished in the
Tyr48Glu mutant suggesting that Cytc phosphorylationmay function as
a switch for the regulation of apoptosis. This ﬁndingmay have a broader
impact for themolecularmechanismunderlying the ability of cancers to
evade apoptosis. Although the kinases that mediate Cytc phosphoryla-
tion are unknown, the fact alone that Cytc can be tyrosine phosphor-
ylatedmight suggest a link to cancer because receptor and non-receptor
tyrosine kinase signaling often causes cancer and it may target Cytc.Reference Method Kinase prediction4
[37]
[37]
HT-MS5
HT-MS
AMP kinase, low conﬁdence
no known motif
[40] MS no known motif
[39] MS no known motif
[48]
[93]
MS, cAMP-dependent
Phospho-epitope-speciﬁc antibody;
TNFα-dependent
no known motif
no known motif
[51]
This study
[39]
[56]
[38]
MS; after ischemia/reperfusion
MS
MS
MS
HT-MS
no known motif
no known motif
Abl kinase, low conﬁdence
CAMK2G, low conﬁdence
PKCε
[51]
[38]
[56]
[56]
[38]
MS; after ischemia/reperfusion
HT-MS
MS
MS
HT-MS
DNA PK, low conﬁdence
no known motif
no known motif
PKCε, low conﬁdence
PKCε and DNA PK, low conﬁdence
[51] MS; after ischemia/reperfusion no known motif
[57] Crystal structure no known motif
(SU) order.
l). The predictions are purely speculative and have to be viewed with extreme caution.
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from human skeletal muscle tissue by high throughput phosphopro-
teomic MS analysis. Thr28 and Ser47 were identiﬁed on Cytc [35],
suggesting that Cytc in this tissue is targeted for phosphorylation by a
signaling pathway that is distinct from heart and liver. The functions
of these phosphorylations remain unknown as does the extent of Cytc
phosphorylation.
Interestingly, all four identiﬁed phosphorylation sites are located
on the right side of Cytc in the conventional view (Fig. 1). It remains to
be seen how phosphorylation of Cytc affects its other functions,
including ROS scavenging under healthy conditions [39,40] and ROS
generationunder stressed conditions through the p66shc pathway [41].
2.4.2. Phosphorylation of cytochrome c oxidase
In 1997, the ﬁrst paper was published suggesting that COX is
phosphorylated on subunit IV by an endogenous kinase after
incubation of mitochondria with [γ-32P]ATP [42]. After that the
cAMP-dependent signaling pathway was studied by several groups in
more detail and therefore deserves an in-depth discussion. The
localization of PKA has been proposed by various investigators to
occur in all mitochondrial compartments, including the outer side of
the outer mitochondrial membrane, the intermembrane space, and
the matrix, but it still remains a controversial issue depending on the
tissue or cell-type and methodology (reviewed in [34]).
In initial work, the Kadenbach group incubated isolated cow heart
COX with PKA, cAMP, and [γ-32P]ATP in vitro [43]. After autoradiog-
raphy they obtained a signal for subunit Vb and a faint signal for
subunits II and/or III. In a follow-up study, using the same approach
they showed that subunit I was also phosphorylated [44]. It must be
emphasized that data obtained with an in vitro approach should be
viewed with great caution, because auxiliary components, such as
scaffolding proteins that mediate speciﬁcity, are absent. For example,
PKA signaling speciﬁcity is mediated through A-kinase anchoring
proteins (AKAPs) that provide a platform for the docking of kinases
and other proteins near membranes and their targets [45]. Therefore,
an in vitro approach should only be considered when similar results
are obtained in vivo. Based on our experience (e.g., comparing
phosphorylation patterns of COX after incubationwith several kinases
in vitro, which did not match results obtained in vivo after stimulation
or inhibition of the corresponding signaling pathway) we strongly
caution the reader against pursuing an in vitro approach.
Our laboratory later revisited cAMP-dependent phosphorylation of
COX in vivo in liver tissue, where cAMP serves as a starvation signal,
triggered by the starvation hormone glucagon. We puriﬁed COX after
treatment with the phosphodiesterase inhibitor theophylline, which
generates high cAMP levels. During the puriﬁcation of mitochondria
and subsequently of COX, we included activated vanadate and
ﬂuoride, two unspeciﬁc tyrosine and serine/threonine phosphatase
inhibitors, respectively. The isolated enzyme was tyrosine phosphor-
ylated on subunit I, whereas the untreated control enzyme did not
show a signal. The site of phosphorylation was identiﬁed by MS as
COX subunit I tyrosine 304. Tyr304 is located adjacent to the oxygen
binding center on COX, an ideal site for enzyme regulation (Fig. 1).
Indeed, Tyr304-phosphorylated COX was fully or strongly inhibited
up to 10 μM Cytc substrate concentrations, even in the presence of
allosteric activator ADP [46]. Control experiments using the physio-
logical hormone glucagon, the strongest physiological signal for
increasing intracellular cAMP levels in liver, or the adenylyl cyclase
activator forskolin, both of which increase intracellular cAMP, showed
a similar inhibitory effect. Notably, Tyr304 phosphorylation cannot be
directly mediated by Ser/Thr-speciﬁc PKA, and it was proposed that a
downstream tyrosine kinase phosphorylates COX [46].
It should be noted that there are distinct tissue-speciﬁc responses
to cAMP and probably other signaling pathways as well. For example,
in neuronal tissue theophylline treatment leads to COX activation
[47]. In heart, theophylline showed no effect, and other heart-speciﬁccAMP inducers such as 3-isobutyl-1-methylxanthine (IBMX) did not
show signiﬁcant effects (unpublished).
One study proposed that cAMP/PKA signaling leads to phosphor-
ylation of COX in heart after ischemia. There, COX subunits I, IV, and
Vb were found to be phosphorylated after ischemia in rabbit hearts
and these phosphorylations were abolished in the presence of alleged
PKA inhibitor H89 [48]. The authors later identiﬁed the phosphory-
lated amino acids byMS to be Ser115 and Ser116 of subunit I, Thr52 of
subunit IV, and Ser40 of subunit Vb [49]. These sites (Fig. 1 and
Table 1) are not PKA consensus sites, and it thus seems unlikely that
PKA signaling is directly involved. Kinase inhibitors often target a
group of kinases, and H89 inhibits at least ﬁve other kinases [50], one
or more of which may be involved in the phosphorylations observed
after ischemia.
TheManfredi group has recently added another interesting facet to
cAMP-dependent signaling by identifying a matrix-localized carbon
dioxide/bicarbonate-regulated adenylyl cyclase [51]. Via sensing of
CO2 generated by the citric acid cycle, this enzyme links nutrient
availability to OxPhos activity. COX is a target of this signaling, and the
authors showed that subunits I and IV are targets of a matrix-localized
PKA. The phosphorylation sites need to be mapped to provide
additional evidence of direct PKA involvement. The effect of matrix
adenylyl cyclase and PKA-dependent signaling is activation of COX
[51], and such activation was shown to improve mitochondrial
function in COX-deﬁcient cells [52]. Additional support for matrix
localized PKA signaling to COX was reported earlier. The RIα
regulatory subunit of PKA can bind to matrix-localized subunit Vb of
COX [53]. It is noteworthy that the observed activation of COX through
matrix-localized adenylyl cyclase and PKA results in the opposite
effect compared to cAMP-dependent in vivo Tyr304 phosphorylation.
This phosphorylation occurs on the intermembrane space side, and in
vitro phosphorylation of COX with commercially available PKA, which
can presumably occur on the matrix and intermembrane space sides,
also leads to COX inhibition [43]. Mapping of the phosphorylation
sites in these studies would shed light on this controversial point.
Additional phosphorylation sites have beenmapped on COX, but the
signaling pathways involved and their functional consequences are
unknown. Those are Tyr11 of subunit IV-1 in isolated cow liver [37],
Ser67 and Ser136 of subunit IV-1, Thr35 and Thr38 of subunit Va in
human HeLa cells by high-throughput MS [36], Ser34 of subunit IV-1,
and Ser4 andThr35of subunit Va in cowheart [54], and Thr11of subunit
VIa heart isoform, which was identiﬁed in the cow heart crystal
structure [55]. The presence of phosphorylation sites in tissue-speciﬁc
isoforms suggests that one of their functions is the provision of a
platform for cell signaling that can mediate tissue-speciﬁc regulation.
This is accompanied by tissue-speciﬁc expression of signaling mole-
cules, such asmitochondrial tyrosine phosphatase PTP 1B, which is only
found in brain but is absent in muscle, heart, and liver tissue [56].
We here present another new phosphorylation, which we
identiﬁed in cow heart COX (Fig. 2). This site, Ser126 on catalytic
subunit II, was unambiguously mapped by MS in three independent
COX isolations, in which the enzyme was isolated from heart tissue
that was immediately frozen on dry-ice, kept on ice for 20 min, and
kept ischemic for 45 min at 37 °C prior to enzyme isolation. The
phosphorylation site is located on the intermembrane space side
(Fig. 1). It is adjacent to but not part of the Cytc-COX docking site
based on computer modeling [57]. In that model the nearest amino
acid of Cytc, Lys27, is located within 11 Å of Ser126. Ser126 is located
at the interface of subunits II and IV, with His109 of subunit IV being
the closest amino acid (within 5 Å). Therefore, this phosphorylation
might be involved in enabling allosteric regulation of COX via ATP and
ADP that bind to subunit IV, which regulation is lost when COX is fully
dephosphorylated [13].
One concern regarding the above studies is that there is little
overlap of phosphorylation sites identiﬁed by different labs. Likely
explanations are that different puriﬁcation protocols were used and
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phosphatase inhibitors. In addition, MS methodology is problematic
with hydrophobic peptides. For COX as a membrane protein this
makes it difﬁcult to identify hydrophobic phospho-epitopes. For
example, phospho-Tyr304 identiﬁcation of hydrophobic subunit I
required signiﬁcant optimization of the sample preparation [46].
There is another series of studies suggesting that COX is a target of
signaling pathways, but in these cases the phosphorylation sites have
not been identiﬁed. Non-receptor tyrosine kinase Src has been shown
to localize to the mitochondrial intermembrane space [58], and it
phosphorylates COX subunit II in osteoblasts [59]. This phosphoryla-
tion leads to COX activation and appears to be important for the bone-
resorbing activity of these cells, whichmight be altered in rheumatoid
arthritis [60]. Another COX regulator is protein kinase Cε (PKCε). In rat
neonatal cardiac myocytes treatment with diacylglycerol or 4β-PMA,
which are PKC activators, resulted in the phosphorylation of an 18 kDa
protein in vitro [61,62]. It was shown that PKCε co-immunoprecipi-
tated with COX and that the radiolabeled 18 kDa band contained
subunit IV. Activation of PKCε resulted in about two- to fourfold
increased COX activity. Src kinase is also phosphorylated and
activated by PKCε [63,64]; however, no tyrosine phosphorylation of
COX subunit II was observed after PKCε stimulation [62]. This might
be explained with tissue speciﬁc differences in cell signaling including
presence or absence of additional required components such as
scaffolding proteins. PKCε is implicated in ischemia/reperfusion
injury, a topic that we will revisit in the next section.
Mitochondrial metabolism shows major alterations in cancer.
Most solid tumors show a reduction in mitochondrial mass of 25–60%
compared to healthy tissue [65]. Cancer cells rely less on respiration
and more on glycolysis, which is known as the Warburg effect [3,4].
The molecular changes that mediate this metabolic switching are now
emerging. Often, cancers show increased receptor tyrosine kinase
signaling, which promotes proliferation and is anti-apoptotic. One
such receptor is epidermal growth factor receptor (EGFR), which is
implicated in numerous cancers including colon, lung, breast, cervical,
and head and neck cancers. Recent research has changed the picture
of how signaling from the plasma membrane is transmitted to the
mitochondria, which now appears to be much more dynamic than
thought previously. Notably, EGFR, upon stimulation with EGF,
translocates to the mitochondria where it directly interacts with
COX subunit II, as shown by phage display screening and co-
immunoprecipitation experiments [66]. EGFR binding to COX is
dependent on the activation state of the receptor and requires
Tyr845 phosphorylation, which is mediated by Src kinase. EGFR in
combination with Src leads to an increase in COX subunit II
phosphorylation in vitro as was shown after incubation with [γ-32P]
ATP followed by autoradiography [67]. However, the phosphorylation
sites still have to be identiﬁed. Importantly, the effect of EGFR/Src
signaling on COX activity is distinct from Src signaling alone discussed
above because it leads to 60% inhibition after cells were treated with
EGF for 20 min. This ﬁnding may explain the mechanism of the
Warburg effect in cancers with upregulated EGFR signaling, and it
remains to be seen if a similar sequence of events wherein the
receptor is translocated to the mitochondria followed by phosphor-
ylation and partial inhibition of COX also applies to other receptor
tyrosine kinases.
The presence of kinases targeting COX implies the presence of
phosphatases to reverse such signaling. Protein tyrosine phosphatase
Shp-2, which is part of the Ras pathway, was the ﬁrst identiﬁed
tyrosine phosphatase that localizes to the mitochondrial intermem-
brane space and the outer mitochondrial membrane in addition to the
cytoplasm [68], and we speculated that it might target COX or Cytc,
the only two components of the ETC with mapped tyrosine
phosphorylation sites (Table 1). Mutations in the Shp-2 encoding
gene PTPN11 account for about 50% of cases with Noonan syndrome
[69], an autosomal dominant disorder characterized by dysmorphicfacial features, congenital heart disease, webbed neck, short stature,
chest deformity, and mental retardation. In these Noonan patients
Shp-2 is constitutively active [70]. We analyzed patient and mouse
cell lines and observed signiﬁcantly increased COX activity [71].
Among OxPhos complexes, only COX and Cytc protein levels were
down-regulated in the mutant cells, suggesting a compensatory
mechanism to counterbalance increased COX activity. Additional
work is needed to establish COX and Cytc as possible direct or indirect
targets of Shp-2. Clearly, dephosphorylation of Tyr48 and Tyr97 on
Cytc and Tyr304 on COX subunit I would result in increased
respiration rates, and all three epitopes are located in the intermem-
brane space, as is Shp-2. Alteration in COX/Cytc activity and their total
amount could affect mitochondrial energy and ROS production.
Indeed, in the Shp-2 mutant cells ATP levels were reduced by 30%
and ROS levels were increased. Both reduced ATP and increased ROS
may interfere with organ development as is observed in the patients
(for a more detailed discussion see [13]).
Another importantmechanism related to cell signaling that acts on
COXmay be through the direct and indirect action of calcium. Calcium
is the proposed strongest signal for mitochondrial activation [72].
Mammalian COX contains a calcium-sodium exchange site in subunit I
[73,74], which may affect COX activity. In addition, calcium was
shown to cause dephosphorylation of most mitochondrial proteins
[75], likely through calcium-activated phosphatases. As described
above, dephosphorylation of COX (at Tyr304, subunit I) and Cytc (Tyr
48 and Tyr97) would result in increased ETC activity. Calcium also
plays a key role during conditions of cellular stress, where it leads to
hyperactive ETC complexes and increased ΔΨm levels, leading to
excessive ROS production as discussed in Section 3.
3. The connection between ETC activity, ΔΨm, energy, and ROS in
human disease: acute inﬂammation and ischemia/reperfusion
injury as two distinct mitochondrial pathologies
The role of OxPhos in human disease can be distilled into two
buzzwords, energy and ROS. Many pathologies present with de-
creased ATP or increased ROS levels, and sometimes a combination of
both. We have previously proposed a model that links ETC activity,
ΔΨm, and the production of ATP and ROS [13]. Based on our model
there are three states, ‘hypoactive,’ ‘healthy,’ and ‘hyperactive’ (Fig. 3),
which may explain many pathophysiological conditions where
mitochondria are involved. In the basic, ‘healthy’ state the OxPhos
complexes are phosphorylated, which reduces their activity. Impor-
tantly, this prevents the generation of ΔΨm levels larger than 140 mV;
i.e., physiologically lower ΔΨm levels are sufﬁcient to inhibit further
proton pumping. This regulation ensures that ΔΨm is maintained
around 120 mV under healthy conditions, which is sufﬁcient for
efﬁcient ATP production [76] but prevents the formation of ROS,
which are generated exponentially at ΔΨm levels exceeding 150 mV
[77].
A further ﬁne-tuning of the regulation of mitochondrial respiration
under healthy conditions is mediated via the allosteric regulation of
COX and Cytc by ATP and ADP discussed above. Respiration rates can
be high if ADP is not limiting and no allosteric ATP-inhibition of COX
occurs [21,23]. Under these conditions the high rate of proton uptake
by ATP contributes to the maintenance of lower ΔΨm levels. When
ADP becomes limiting the allosteric ATP-inhibition inhibits respira-
tion and further proton pumping. This occurs already at healthy ΔΨm
levels, because maximal rates of ATP synthesis by ATP synthase occur
at ΔΨm=100–120 mV [76]. It should be noted, however, that
phosphorylation of OxPhos components appears to be the overarch-
ing regulatory mechanism preventing unhealthy high ΔΨm values
even in the presence of ADP. This is so because ΔΨm values during
state 3 reported for isolated mitochondria, with presumably dephos-
phorylated OxPhos complexes, are often higher (N140 mV) than those
reported for intact cells. For example, a ΔΨm value of 172 mV was
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During state 4, mitochondria isolated according to traditional pro-
tocols with dephosphorylated OxPhos complexes can generate ΔΨm
levels of 200 mV and above [13]. Isolated mitochondria are morpho-logically and functionally distinct from mitochondria in intact cells
and show unphysiologically high COX activities [79].
To exemplify the two distinct pathological states of our model,
‘hypoactive’ and ‘hyperactive,’wewill discuss acute inﬂammation and
Fig. 3. Proposed model linking COX activity with the mitochondrial membrane
potential, ATP and ROS production under healthy conditions and in two distinct
pathological states. Under healthy conditions (middle) COX and Cytc are phosphor-
ylated leading to a partial inhibition of respiration (Cytc is not shown). This generates
healthy mitochondrial membrane potentials ΔΨm of about 120 mV, sufﬁcient for
efﬁcient ATP generation but too low for ROS production. Two distinct pathological
conditions are shown, both of which can lead to cell death: 1) acute inﬂammatory
signaling via TNFα causes COX subunit I Tyr304 phosphorylation (pY304), leading to
strong COX inhibition, decreased ΔΨm levels, and eventually energy depletion. In
patients with sepsis this model would explain organ failure and death through energy
failure; 2) the opposite mode of action takes place during ischemia/reperfusion. During
ischemia, nutrients and oxygen become depleted. This stress causes excessive calcium
release leading to changes in the phosphorylation pattern and/or dephosphorylation of
Cytc and COX. The electron transport chain is now ‘primed’ for hyperactivity. During
reperfusion, in the presence of oxygen and metabolites, OxPhos resumes to rebuild
ΔΨm and ATP. Since the ETC complexes are in a hyperactive state, ﬂux is maximal,
which leads to a hyperpolarization of ΔΨm, reaching levels at which excessive ROS are
generated. ROS cause extensive damage to the cell and trigger apoptosis.
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inﬂammation results in decreased ΔΨm and energy levels. In contrast,
the hyperactive state during reperfusion following ischemia results in
ΔΨm hyperpolarization and ROS production. Both states can result in
cell death through these distinct pathways.3.1. Role of cytochrome c oxidase and cytochrome c in acute inﬂammation:
the hypoactive state and the energy crisis
Sepsis is an acute inﬂammatory condition that affects the entire
body and represents a potentially life-threatening systemic inﬂam-
matory state. Sepsis is sometimes referred to as blood poisoning in the
non-medical literature. In the United States, sepsis develops in
750,000 people annually with more than 210,000 deaths, which
makes it the leading cause of mortality in patients in intensive care
units [80]. Sepsis was formerly attributed to a pathogenic infection of
the blood, but the deﬁnition has changed in modern times to reﬂect
the body's inﬂammatory response to severe insult or injury, including
the development of multiple organ dysfunction syndrome (MODS)
[81]. Therefore, the combination of an infection with an overly active
immune response can lead to organ dysfunction and eventual death.Fig. 2.Nano-LC-ESI-MS/MS analysis of Blue Native-PAGE-separated, BrCN and trypsin cleaved
(MS/MS) the phosphopeptides were enriched with titanium dioxide as described [54,12
localization of Ser126 as the site of phosphorylation was possible after fragmentation of the
the triply charged ion (474.3 Th) with electron transfer dissociation (ETD). A, the CID-MS/MS
of the precursor ion. The y10 and b3 fragment ions as well as the neutral loss ions y9 and b5 (
specifying the peptide amino acid sequence including the phosphosite-speciﬁc C-terminal z8
of the fragmentation pattern phosphorylation of Thr125 was excluded by the presence of iExcept for mutations in the pathogen recognition toll-like receptor
4 (TLR4) [82], the only other known genetic predictor for survival
after sepsis is a particular mitochondrial DNA composition, the
haplogroup H. Mitochondrial haplogroups are grouped based on a
relatively small number of mitochondrial DNA polymorphisms that
are preserved in certain populations, for example from different
continents. Those subtle changes have been linked to certain
phenotypes and pathologies, such as longevity or male fertility [83].
Patients belonging to haplogroup H, which is common in Europeans,
have a more than twofold increased chance of survival after sepsis
compared to patients in other haplogroups [84]. This ﬁnding suggests
that mitochondria play a key role in acute inﬂammation.
Given the role of COX and Cytc in providing energy for all cellular
functions and the role of Cytc in the regulation of cellular survival and
apoptosis, it is no surprise that both enzymes have been implicated in
the pathology of sepsis. The terminal step of the ETC is a logical
functional target: it is characterized by poor tissue oxygen extraction
and utilization as seen in patients, suggesting that the ETC is a target of
inﬂammatory signaling. In fact, it was hypothesized in the past that
dysfunction of mitochondrial electron transport may be responsible
for some of the symptoms of sepsis because direct systemic delivery of
oxygen during the course of sepsis was shown to be ineffective [85].
This indicated that oxygen utilization rather than uptake is impaired, a
model referred to as cytopathic hypoxia [86].
Lipopolysaccharide (LPS, or endotoxin) is often used in animal
experiments to cause a septic state and leads to the production of pro-
inﬂammatory cytokines, including tumor necrosis factor α (TNFα)
through the activation of TLR4. TNFα is a key cytokine that is induced as
part of the inﬂammatory cascade that leads to the septic state. TNFα
affects metabolism in that it induces the production of lactate in vitro
and in vivo [87,88], indicating a switching from aerobic to glycolytic
energymetabolism. In LPS-treated rats, ETC complexes I, II, and IVwere
down-regulated both at the transcript and protein level within 24 h
after treatment [89]. It was further demonstrated that early in sepsis
oxidation of Cytc by COX is competitively and reversibly inhibited; in
later stages (at 48 h), it becomes noncompetitive and irreversible [90].
Rats subjected to cecal ligation and puncture, another animal model for
sepsis, showed unchanged muscle tissue oxygen levels between sham
control and septic animals but the septic animals had reducedATP levels
[91]. Another study performed by the Kozlov group showed that
induction of endotoxic shock through LPS treatment resulted in an early
increase in blood levels of TNFα and70%decreasedATP levels after 8 h, a
critical time atwhich about 30% of the animals are dead andmost of the
remaining animals surviving [92].
All the above reports indicate that metabolic changes occur at the
level of OxPhos during sepsis, but themolecular mechanism remained
unclear. To gain more insight into this question we investigated
the effect of TNFα on cow and mouse liver tissue and mouse
hepatocytes in culture. TNFα treatment of bovine and murine liver
homogenates produced a 60% reduction of COX activity within 5 min
after treatment [93]. Importantly, isolation of cow COX revealed
phosphorylation of tyrosine 304 of subunit I after TNFα, which was
identiﬁed with a phospho-epitope-speciﬁc antibody. This is the same
site that is targeted for phosphorylation by the cAMP-dependent
pathway in liver discussed above. TNFα treatment decreased the
mitochondrial membrane potential and resulted in 35% and 64%
reduction of cellular ATP levels in mouse hepatocytes and H2.35 cells
[93]. It will be interesting to see if Cytc is also targeted by TNFα
signaling, which could augment the effect of COX phosphorylation.COX subunit II isolated from cow heart. Prior to analysis by tandemmass spectrometry
0]. The MS/MS spectrum unambiguously identiﬁes the peptide IPTpSELKPGELR. The
doubly charged precursor ion (710.5 Th) with collision-induced dissociation (CID) and
spectrum contains a CID-typical neutral loss of phosphoric acid from the phosphoserine
both -H3PO4) indicate phosphoserine. B, the ETD fragmentation resulted in a spectrum
and z9 ions and the corresponding N-terminal c3 and c4 ions. Furthermore, on the basis
ons c2, z9, and z10.
606 M. Hüttemann et al. / Biochimica et Biophysica Acta 1817 (2012) 598–609A question that emerges is: why did such a response evolve, which
can lead to death in humans? A likely explanation is that, in a day-to-
day context, the organism constantly has to defeat pathogens at a
more local setting, e.g., after a small skin cut. Some pathogens seize
control of the host infrastructure and energy production system. For
example, chlamydiae express a number of nucleotide transporters
that facilitate the uptake of molecules such as ATP [94]. Therefore,
shutting down OxPhos locally at the site of infection slows down
pathogenic growth because essential metabolites are no longer
provided by the host. In the rare situation of a systemic inﬂammation
this response can get out of control, leading to MODS and death due to
energy failure of entire organs.
In summary, our model proposes that acute inﬂammatory
signaling leads to phosphorylation of COX and strong enzyme
inhibition, reduced membrane potentials, and consequently de-
creased energy levels (Fig. 3). If ATP levels drop below a threshold,
such as 30% in liver tissue [92], organ function cannot be maintained,
leading to organ failure.
3.2. Role of cytochrome c oxidase and cytochrome c in brain ischemia/
reperfusion injury: the hyperactive state and excessive reactive oxygen
species
Cerebral ischemia/reperfusion injury is caused by interruption of
blood ﬂow to the brain. This can occur in multiple pathologies, the
most common being ischemic stroke. Ischemic stroke occurs when
blood ﬂow to a region of the brain is prevented by occlusion of a
cerebral blood vessel. Restoration of blood ﬂow to ischemic tissue is
necessary to limit tissue damage; however restoration of oxygen and
nutrients to stressed tissue leads to additional damage. This damage is
called reperfusion injury and contributes greatly to the overall
severity of tissue damage. The brain also undergoes ischemia/reperfu-
sion injury in the setting of cardiac arrest followed by resuscitation.
Cardiac failure results in complete cerebral ischemia, and resuscita-
tion of the arrested patient initiates reperfusion of the brain. Both
ischemic stroke and cardiac arrest/resuscitation result in extensive
morbidity and mortality throughout the population. Stroke is the 3rd
leading cause of death and disability in the US and only 10% of
resuscitated patients leave the hospital neurologically intact and can
resume their former lifestyles [95]. These statistics demonstrate the
dramatic need for greater understanding of ischemia/reperfusion
injury in the brain and for targeted therapies to treat these disease
processes.
Mitochondria play multiple roles in the setting of cerebral
ischemia/reperfusion injury both as a cause of neuronal damage and
a site of intracellular injury. We propose that there are three distinct
phases of altered COX activation during the progression of ische-
mia/reperfusion injury: 1) the ischemic starvation phase, 2) the
reperfusion-induced hyperactivation phase, and 3) the mitochondrial
dysfunction phase. The role of COX and Cytc phosphorylation in these
distinct activation proﬁles remains largely unknown. However, many
studies have identiﬁed critical alterations in COX activity during the
progression of reperfusion injury, suggesting an important role for cell
signaling in these changes.
During the ischemic starvation phase, tissue becomes oxygen
deprived, therebydepletingCOXof its terminal substrate for respiration.
In the ischemic brain, this is rapidly followed byATP depletion, elevated
ADP, and, importantly, an increase inmitochondrial calcium [96]. There
aremultiple cell signaling pathways activated by ischemia that signal to
themitochondria to increase ATP production in order to compensate for
the rapid loss of energy. Many phosphorylation/dephosphorylation
events have been shown to occur on COX that could, in theory, increase
ATP production in ischemic tissue if oxygen were present. Of particular
interest is the role of mitochondrial calcium during ischemia and early
reperfusion. Mitochondrial calcium concentrations increase during
ischemia when intracellular pumps fail, and mitochondria activelysequester calcium during early restoration of blood ﬂow. This results in
dramatically increased mitochondrial calcium concentrations [97]. As
discussed above, calcium is themost important signal formitochondrial
activation [72] and induces dephosphorylation of most mitochondrial
proteins [75]. Calciumhas been shown in vitro to lead tohyperactivation
of COX throughahigher basal activity and loss of the allosteric inhibition
byATP [43]. This is likely causedby changes in thephosphorylation state
of COX, which is further supported by the ﬁnding that dephosphory-
lation of COX makes the enzyme insensitive to ATP and ADP [13]. Thus,
the loss of allosteric control does not appear to be a direct effect of
calcium on COX, but is caused indirectly by dephosphorylation of COX,
presumably by a calcium-dependent phosphatase [43]. Increased basal
COX activity in combination with a loss of allosteric inhibition by ATP
could cause profound problems when reperfusion of the tissue is
initiated, as this would lead to hyperpolarization of mitochondrial ΔΨm
(Fig. 3). Itwas shown that treatmentof brainmitochondriawith calcium
increased state 4 respiration by 141% [98], which may be explained by
COX dephosphorylation. These events would render COX “primed” for
hyperactivity resulting in deleterious effectswhenoxygen andnutrients
are restored upon reperfusion.
Based on our model (Fig. 3), upon restoration of blood ﬂow,
oxygen and nutrients reach stressed mitochondria and a COX enzyme
that has been post-translationally modiﬁed to increase its activity.
These alterations aid in restoration of ΔΨm, and reestablishment of
cellular energy levels [99]. In fact, mitochondria rapidly become re-
energized and ΔΨm is quickly restored within 5 min [99]. However, in
this hyperactive state, the ETC generates pathologically high ΔΨm
levels, and mitochondrial hyperpolarization leads to an exponential
increase in ROS generation atmembrane potentials exceeding 140 mV
[77]. Additionally, measurements of ROS following ischemia indicate
that the majority of mitochondrial ROS are created during this early
reperfusion interval [100], and the ETC is a primary source of ROS
during reperfusion [101]. Indeed, Liu and coworkers demonstrated
that reperfusion of ischemic brain results in a rapid restoration of
ΔΨm, followed by a transient hyperpolarization of ΔΨm, which lasts
for about 8 min in the mouse brain [102]. This effect is lost when
animals undergo ischemic preconditioning, a method shown to
produce a robust effect in reducing ROS generation by the mitochon-
dria, which makes it profoundly neuroprotective. These ﬁndings
position COX as a potential regulatory site that can indirectly control
ROS generation by regulating overall ETC ﬂux, thereby controlling
ΔΨm. This also suggests that regulation of ETC activity and/or ΔΨm
hyperpolarization provides targets for therapeutic intervention.
Neuroprotective therapies designed to prevent ΔΨm hyperpolariza-
tion have been effective at both preventing ROS generation by the
mitochondria and preventing neuronal cell death [103]. In agreement
with this hypothesis, mild mitochondrial uncoupling with FCCP
reduces ΔΨm hyperpolarization, prevents ROS generation, and
minimizes cell death in models of cardiac ischemia [104], traumatic
brain injury [105], and peroxide-induced neuronal death [106].
Additionally, the converse is also true; promoting hyperpolarization
during reperfusion by knocking out mitochondrial uncoupling protein
2 (UCP2) results in increased ROS generation and neuronal damage
[103].
The ﬁnal phase in the progression of brain ischemia/reperfusion
injury is known as mitochondrial dysfunction or secondary energy
failure. In this phase, COX activity becomes dramatically reduced
throughout the progression of reperfusion injury, eventually culmi-
nating with energy failure and cell death [107–109]. The role of COX
phosphorylation in reduced COX activity during this late stage is
currently unknown. Multiple studies have suggested that diminished
mitochondrial respiration is likely caused by oxidative damage to the
mitochondria [110,111]. Interestingly, while COX appears to be a
major site of depressed respiratory capacity [107], COX is particularly
resistant to direct oxidative damage [111]. Oxidative damage to the
mitochondria can occur on proteins involved in respiration as well as
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mitochondrial membrane lipid cardiolipin, which is required for
proper membrane insertion and function of COX and other OxPhos
components, can become oxidized [112]. Oxidative damage to the
mitochondria results in eventual failure of OxPhos. In addition, ROS
production during the reperfusion phase and subsequent mitochon-
drial dysfunction activate the intrinsic apoptotic pathway, thereby
committing the cell to death. In summary, this model puts forth the
hypothesis that ischemia-induced stress leads to changes in the
phosphorylation state of COX. This renders COX hyperactive and leads
to mitochondrial ROS generation during the initial stages of
reperfusion. ROS can trigger apoptosis, and they cause damage that
initiates ETC and COX hypoactivity and mitochondrial dysfunction
during later reperfusion. It is thus possible that therapeutic interven-
tion at the level of COX may be a potent neuroprotective therapy in
the context of brain reperfusion injury. If the alterations, i.e.,
phosphorylations, to COX that increase its activity can be targeted
to prevent mitochondrial hyperpolarization and subsequent ROS
generation, it may be possible to prevent the downward spiral of
mitochondrial dysfunction and cell death.
The role of Cytc in ischemia/reperfusion injury is twofold. The loss of
Cytc function is a contributing factor to mitochondrial dysfunction or
secondary energy failure, and Cytc release from mitochondria is an
initiating event inmitochondrial type II apoptosis and cell death. Recent
identiﬁcation of phosphorylation sites on Cytc discussed above that
regulates its activity in respiration and apoptosis raises the possibility
that Cytc is actively targeted by stress signaling during ischemia/
reperfusion. Because phosphorylation of Cytc partially inhibits respira-
tion, if stress-induced signaling also targets Cytc for dephosphorylation,
this would lead to increased ETC ﬂux and further contribute to the
hyperpolarization of ΔΨm. In support of this hypothesis, we found that
Cytc isolated from ischemic brain showed no signs of phosphorylation
(unpublished data). In contrast to phosphorylated Cytc, this depho-
sphoryated Cytc would have the full capability to bind to Apaf1 and
trigger downstream caspase activation [10].
In the progression of brain reperfusion injury, mitochondrial
respiration begins to diminish [108,113], and mitochondrial dysfunc-
tion eventually culminates in cell death. Diminished respiratory
capacity precedes the release of Cytc into the cytosol. Therefore, a lack
of Cytc availability cannot account for impaired respiration during
early reperfusion. One possible factor in mitochondrial dysfunction is
peroxidation of cardiolipin by Cytc, an important step in the execution
of the apoptotic cascade [114]. Cardiolipin tethers Cytc to the inner
mitochondrial membrane, whereas peroxidation of cardiolipin allows
disassociation of Cytc and liberates it into a free-ﬂoating pool [114].
Extensive peroxidation of cardiolipin has been demonstrated during
brain reperfusion, and is associated with initiation of apoptosis.
Interestingly, cardiolipin peroxidation might be regulated by phos-
phorylation of tyrosine sites on Cytc, as suggested by studies using
phosphomimetic mutant Cytc [115].
During the ﬁnal stages of reperfusion injury, Cytc participates in cell
demise by initiating apoptosis. Multiple studies have demonstrated the
neuroprotective and antiapoptotic effect of therapies designed to
activate cell survival signaling and prevent apoptotic release of Cytc
[116,117]. However, the idea that stimulation of cell signaling could lead
to phosphorylation of Cytc, thereby suppressing apoptosis, has yet to be
investigated. In summary, phosphorylation events that regulate COX
and Cytcmay be novel targets for therapeutic intervention to limit the
damage caused by ischemia/reperfusion.
4. Conclusion
COX and Cytc show all three main regulatory features found in key
metabolic enzymes: isoform expression, allosteric control, and
phosphorylation. This points to the importance of the regulation of
the terminal step of the ETC, and supports its suggested rate-limitingrole for overall ETC ﬂux in intact cells. This has direct implications for
energy and ROS production, which are dysregulated in numerous
human diseases.
In higher organisms cell signaling cascades function as communi-
cation networks that allow adjustment of cell, organ, and organismal
function to varying internal and environmental conditions, ranging
from complete rest (e.g., hibernation) to strenuous exercise. To study
the effect of signaling cascades on mitochondrial function important
precautions have to be taken to preserve posttranslational modiﬁca-
tions. To maintain the physiological phosphorylation state, phospha-
tase inhibitors have to be included at all steps during the isolation of
mitochondrial proteins, and detailed protocols are available for both
Cytc and COX [38,118].
Another crucial aspect that deserves special attention is that
signaling must not be generalized, and instead has to be carefully
evaluated in a tissue-speciﬁc context. We have touched on this topic
discussing cAMP-dependent signaling that, depending on the tissue,
can lead to distinct and sometimes opposing effects. The expression of
tissue-speciﬁc isoforms further underlines this notion since it can
provide tissue-speciﬁc targets for phosphorylation as is the case for
COX subunit VIa and likely others that have yet to be identiﬁed.
Phosphorylation sites have been mapped in all OxPhos complexes
and it is therefore possible that strong regulatory effects on enzyme
activity, e.g., as seen for COX subunit I Tyr304 phosphorylation, will be
reported for complexes I, II, III, and V in future work. Identiﬁcation of
kinases and phosphatases that directly act on OxPhos would also
make possible the utilization of genetic methods to further pinpoint
the role of posttranslational regulation. This research direction holds
tremendous translational potential because it would allow targeted
therapeutic intervention in conditions such as sepsis, ischemia/re-
perfusion injury, cancer, and many others.Acknowledgements
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